Abstract
Apoptosis is a biological feature, which causes programmed cell death. It consists of two pathways, namely extrinsic and intrinsic, and mitochondria areĀ the site of apoptotic process completion. An abnormality in theĀ apoptotic process can make cells immoral, which is one of the major characteristics of cancer cell formation and cancer development. Chemotherapeutic molecules, which have been used as anticancer drugs, or drugs under investigations, have mostly designed in a way that they can revert apoptotic abnormalities or induce apoptosis. This book chapter discusses the apoptotic process and its abnormalities in cancer cells, and how chemotherapeutic drugs can induce apoptosis, with most advanced and updated findings on mechanisms of action.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Maghsoudi N, Zaketi Z, Lockshin R (2012) Programmed cell death and apoptosisāwhere it came from and where it is going: from Elie Metchnikoff to the control of caspases. Exp Oncol 34:146ā152
Raff M, Alberts B, Lewis J et al (2002) Molecular biology of the cell, 4th edn. National Center for Biotechnology InformationĆs Bookshelf
Knight T, Luedtke D, Edwards H et al (2019) A delicate balanceāthe BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics. Biochem Pharmacol 162:250ā261
Khan KH, Blanco-Codesido M, Molife LR (2014) Cancer therapeutics: targeting the apoptotic pathway. Crit Rev Oncol Hematol 90:200ā219
Koch A, Roth W, Steffek T et al (2008) Impact of apoptosis in acute rejection episodes after heart transplantation: immunohistochemical examination of right ventricular myocardial biopsies. Transplant Proc 40:943ā946
Mirzayans R, Andrais B, Kumar P et al (2017) Significance of wild-type p53 signaling in suppressing apoptosis in response to chemical genotoxic agents: impact on chemotherapy outcome. Int J Mol Sci 18:928
Curtin JF, Cotter TG (2003) Apoptosis: historical perspectives. Essays Biochem 39:1ā10
Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wideranging implications in tissue kinetics. Br J Cancer 26:239ā257
Zaman S, Wang R, Gandhi V (2014) Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma 55:1980ā1992
Lomonosova E, Chinnadurai G (2008) BH3-only proteins in apoptosis and beyond: an overview. Oncogene 27:S2āS19
Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495ā516
Lopez J, Tait S (2015) Mitochondrial apoptosis: killing cancer using the enemy within. Br J Cancer 112:957ā962
Hassan M, Watari H, AbuAlmaaty A et al (2014) Apoptosis and molecular targeting therapy in cancer. Biomed Res Int 2014:150845
Green DR, Llambi F (2015) Cell death signaling. Cold Spring Harb Perspect Biol 7:a006080
Goldar S, Khaniani MS, Derakhshan SM et al (2015) Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev 16:2129ā2144
Goonesinghe A, Mundy ES, Smith M et al (2005) Pro-apoptotic Bid induces membrane perturbation by inserting selected lysolipids into the bilayer. Biochem J 387:109ā118
Boatright KM, Salvesen GS (2003) Mechanisms of caspase activation. Curr Opin Cell Biol 15:725ā731
Szegezdi E, Logue SE, Gorman AM et al (2006) Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 7:880ā885
Saleem M, Qadir MI, Perveen N et al (2013) Inhibitors of apoptotic proteins: new targets for anticancer therapy. Chem Biol Drug Des 82:243ā251
Fernald K, Kurokawa M (2013) Evading apoptosis in cancer. Trends Cell Biol 23:620ā633
Dewson G, Kluck RM (2010) Bcl-2 family-regulated apoptosis in health and disease. Cell Health Cytoskelet 2:22
Wei Y, Fan T, Yu M (2008) Inhibitor of apoptosis proteins and apoptosis. Acta Biochim Biophys Sin Shanghai 40:278ā288
Fink SL, Cookson BT (2005) Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun 73:1907ā1916
OāBrien MA, Kirby R (2008) Apoptosis: a review of pro-apoptotic and anti-apoptotic pathways and dysregulation in disease. J Vet Emerg Crit Car 18:572ā585
Lavrik I, Golks A, Krammer PH (2005) Death receptor signaling. J Cell Sci 118:265ā267
Ashkenazi A, Pai RC, Fong S et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155ā162
Pukac L, Kanakaraj P, Humphreys R et al (2005) HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92:1430ā1441
Leong S, Cohen RB, Gustafson DL et al (2009) Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol 27:4413ā4421
Mom CH, Verweij J, Oldenhuis CN et al (2009) Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 15:5584ā5590
Sun W, Nelson D, Alberts S et al (2011) Phase Ib study of mapatumumab in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) and chronic viral hepatitis. J Clin Oncol 29:261ā261
Georgakis GV, Li Y, Humphreys R et al (2005) Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 130:501ā510
Kaplan-Lefko PJ, Graves JD, Zoog SJ et al (2010) Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther 9:618ā631
Paz-Ares L, BĆ”lint B, de Boer RH et al (2013) A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced nonāsmall-cell lung cancer. J Thorac Oncol 8:329ā337
Demetri GD, Le Cesne A, Chawla SP et al (2012) First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study. Eur J Cancer 48:547ā563
Kindler H, Richards D, Garbo L et al (2012) A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol 23:2834ā2842
Camidge DR, Herbst RS, Gordon MS et al (2010) A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 16:1256ā1263
Forero-Torres A, Shah J, Wood T et al (2010) Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm 25:13ā19
Sharma S, de Vries EG, Infante JR et al (2014) Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Investig New Drugs 32:135ā144
Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9:47ā59
Emi M, Kim R, Tanabe K et al (2005) Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res 7:R940
Kim R, Emi M, Matsuura K et al (2007) Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Ther 14:1ā11
Jahrsdƶrfer B, Jox R, MĆ¼hlenhoff L et al (2002) Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukoc Biol 72:83ā92
Kang MH, Reynolds CP (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15:1126ā1132
Cao XX, Mohuiddin I, Ece F et al (2001) Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 25:562ā568
Kang MH, Wan Z, Kang YH et al (2008) Mechanism of synergy of N-(4-hydroxyphenyl) retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 100:580ā595
Loberg RD, McGregor N, Ying C et al (2007) In vivo evaluation of AT-101 (R-(ā)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. Neoplasia 9:1030ā1037
Zerp SF, Stoter R, Kuipers G et al (2009) AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis. Radiat Oncol 4:47
Mohammad RM, Wang S, Aboukameel A et al (2005) Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL [(ā)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 4:13ā21
Nguyen M, Marcellus RC, Roulston A et al (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A 104:19512ā19517
Oltersdorf T, Elmore SW, Shoemaker AR et al (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677ā681
Tse C, Shoemaker AR, Adickes J et al (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68:3421ā3428
Ashkenazi A, Fairbrother WJ, Leverson JD et al (2017) From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov 16:273ā284
Morales M-C, PĆ©rez-Yarza G, Nieto-Rementeria N et al (2005) Intracellular glutathione levels determine cell sensitivity to apoptosis induced by the antineoplastic agent N-(4-hydroxyphenyl) retinamide. Anticancer Res 25:1945ā1951
Roberts AW, Seymour JF, Brown JR et al (2012) Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30:488ā496
Vandenberg CJ, Cory S (2013) ABT-199, a new Bcl-2āspecific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 121:2285ā2288
Pekarsky Y, Balatti V, Croce CM (2018) BCL2 and miR-15/16: from gene discovery to treatment. Cell Death Differ 25:21ā26
Souers AJ, Leverson JD, Boghaert ER et al (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202ā208
Flinn IW, Brunvand M, Choi MY et al (2015) Safety and efficacy of a combination of venetoclax (GDC-0199/ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia-results from a phase 1b study (GP28331). Blood 126:494
Ma S, Brander DM, Seymour JF et al (2015) Deep and durable responses following venetoclax (ABT-199/GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from a phase 1b study. Blood 126:830
Lessene G, Czabotar PE, Sleebs BE et al (2013) Structure-guided design of a selective BCL-X L inhibitor. Nat Chem Biol 9:390ā397
Zhang H, Xue J, Hessler P et al (2015) Genomic analysis and selective small molecule inhibition identifies BCL-X L as a critical survival factor in a subset of colorectal cancer. Mol Cancer 14:126
Leverson J, Zhang H, Chen J et al (2015) Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis 6:e1590
Caenepeel S, Brown SP, Belmontes B et al (2018) AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov 8:1582ā1597
Daly T, Ippolito T, Gu JJ et al (2019) MCL-1 inhibition by the selective MCL-1 inhibitor AMG-176 induces in vitro activity against burkitt lymphoma cell lines and synergistically enhances the cytotoxic effect of chemotherapy and BH3 mimetics. Blood 134:5303
Rathore R, McCallum JE, Varghese E et al (2017) Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). Apoptosis 22:898ā919
Qin Q, Zuo Y, Yang X et al (2014) Smac mimetic compound LCL161 sensitizes esophageal carcinoma cells to radiotherapy by inhibiting the expression of inhibitor of apoptosis protein. Tumour Biol 35:2565ā2574
Tchoghandjian A, SoubƩran A, Tabouret E et al (2016) Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152. Cell Death Dis 7:e2325
Condon SM, Mitsuuchi Y, Deng Y et al (2014) Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. J Med Chem 57:3666ā3677
Eckhardt S, Gallant G, Sikic B et al (2010) Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors. J Clin Oncol 28:2580ā2580
Belz K, Schoeneberger H, Wehner S et al (2014) Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly. Blood 124:240ā250
LaCasse EC, Cherton-Horvat GG, Hewitt KE et al (2006) Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res 12:5231ā5241
Nakahara T, Kita A, Yamanaka K et al (2007) YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 67:8014ā8021
Carrasco RA, Stamm NB, Marcusson E et al (2011) Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther 10:221ā232
Li J, Khan M, Wei C et al (2017) Thymoquinone inhibits the migration and invasive characteristics of cervical cancer cells SiHa and CaSki in vitro by targeting epithelial to mesenchymal transition associated transcription factors Twist1 and Zeb1. Molecules 22:2105
Tania M, Shawon J, Saif K et al (2019) Cordycepin downregulates Cdk-2 to interfere with cell cycle and increases apoptosis by generating ROS in cervical cancer cells: in vitro and in silico study. Curr Cancer Drug Targets 19:152ā159
Khan MA, Chen H-c, Wan X-x et al (2013) Regulatory effects of resveratrol on antioxidant enzymes: a mechanism of growth inhibition and apoptosis induction in cancer cells. Mol Cells 35:219ā225
Tamm I, Kornblau SM, Segall H et al (2000) Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 6:1796ā1803
Rƶdel F, Frey B, Leitmann W et al (2008) Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 71:247ā255
Farhood B, Najafi M, Salehi E et al (2019) Disruption of the redox balance with either oxidative or anti-oxidative overloading as a promising target for cancer therapy. J Cell Biochem 120:71ā76
Khan MA, Tania M, Zhang D-z et al (2010) Antioxidant enzymes and cancer. Chinese J Cancer Res 22:87ā92
Suen D-F, Norris KL, Youle RJ (2008) Mitochondrial dynamics and apoptosis. Genes Dev 22:1577ā1590
He L, He T, Farrar S et al (2017) Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen species. Cell Physiol Biochem 44:532ā553
Morioka S, Omori E, Kajino T et al (2009) TAK1 kinase determines TRAIL sensitivity by modulating reactive oxygen species and cIAP. Oncogene 28:2257ā2265
Shi Y, Nikulenkov F, Zawacka-Pankau J et al (2014) ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death Differ 21:612ā623
Hattori K, Naguro I, Runchel C et al (2009) The roles of ASK family proteins in stress responses and diseases. Cell Commun Signal 7:9
Aggarwal V, Tuli HS, Varol A et al (2019) Role of reactive oxygen species in cancer progression: molecular mechanisms and recent advancements. Biomol Ther 9:735
Coriat R, Leconte M, Kavian N et al (2011) Mangafodipir protects against hepatic ischemia-reperfusion injury in mice. PLoS One 6:e27005
Son A-R, Ahn J, Song J-Y (2014) Niclosamide enhances ROS-mediated cell death through c-Jun activation. Biomed Pharmacother 68:619ā624
Coriat R, Marut W, Leconte M et al (2011) The organotelluride catalyst LAB027 prevents colon cancer growth in the mice. Cell Death Dis 2:e191
Cha JH, Choi YJ, Cha SH et al (2012) Allicin inhibits cell growth and induces apoptosis in U87MG human glioblastoma cells through an ERK-dependent pathway. Oncol Rep 28:41ā48
Nicco C, Batteux F (2018) ROS modulator molecules with therapeutic potential in cancers treatments. Molecules 23:84
Seymour JF (2016) Effective mitigation of tumor lysis syndrome with gradual venetoclax dose ramp, prophylaxis, and monitoring in patients with chronic lymphocytic leukemia. Ann Hematol 95:1361ā1362
Hu J, Duan Z, Yu G et al (2019) Bcl-2 inhibitors as sensitizing agents for cancer chemotherapy. In: Protein kinase inhibitors as sensitizing agents for chemotherapy. Elsevier, Amsterdam, pp 151ā168
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2020 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Junaid, M., Akter, Y., Afrose, S.S., Tania, M., Khan, M.A. (2020). Apoptotic Cell Death: Important Cellular Process as Chemotherapeutic Target. In: Tuli, H.S. (eds) Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models. Springer, Singapore. https://doi.org/10.1007/978-981-15-7586-0_4
Download citation
DOI: https://doi.org/10.1007/978-981-15-7586-0_4
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-7585-3
Online ISBN: 978-981-15-7586-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)